Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 1608 to 1657 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1608\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KATANIN P80 SUBUNIT B 1; KATANIN (80 KDA); KATANIN P80 (WD40-CONTAINING) SUBUNIT B 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0440508\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.183648\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239865395\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KATNB1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1609\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KATANIN P60 SUBUNIT A 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.154124\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.64258\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239851847\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KATNA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1610\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 1 ISOFORM B; DNA-BINDING PROTEIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.298042\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.24282\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239811075\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TMEM189\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1611\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UTP--GLUCOSE-1-PHOSPHATE URIDYLYLTRANSFERASE 2 (EC 2.7.7.9) (UDP- GLUCOSE PYROPHOSPHORYLASE 2) (UDPGP 2) (UGPASE 2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.203313\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.847819\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239807081\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UGP2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1612\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 2; 1 ALPHA,25-DIHYDROXYVITAMIN D3-INDUCIBLE; ENTEROCYTE DIFFERENTIATION PROMOTING FACTOR; METHYL METHANESULFONATE SENSITIVE 2, S. CEREVISIAE, HOMOLOG OF. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.274194\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.14341\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239803745\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UBE2V2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1613\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MITOCHONDRIAL RIBOSOMAL PROTEIN L30 ISOFORM A. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0388254\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.161954\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239731035\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MRPL30\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1614\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASE REGULATORY SUBUNIT S10B (PROTEASOME SUBUNIT P42) (P44) (CONSERVED ATPASE DOMAIN PROTEIN 44) (CADP44). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.19046\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.96583\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239730317\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMC6\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1615\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.153801\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.641812\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239635594\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C20orf11\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1616\vspace{3pt}}&&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0384502\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.160453\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.239635283\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
MAEA\vspace{3pt}}\\\cline{1-1}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1617\vspace{3pt}}&&&&&\parbox{\wcF}{\vspace{3pt}\noindent
RMND5A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1618\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ACID CERAMIDASE PRECURSOR (EC 3.5.1.23) (ACYLSPHINGOSINE DEACYLASE) (N-ACYLSPHINGOSINE AMIDOHYDROLASE) (AC) (PUTATIVE 32 KDA HEART PROTEIN) (PHP32). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.083902\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.35015\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239617307\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ASAH1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1619\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
OLIGOPHRENIN 1. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0153184\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.063934\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239597084\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
OPHN1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1620\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SENESCENCE MARKER PROTEIN-30 (SMP-30) (REGUCALCIN) (RC). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0724203\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.302259\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239596836\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RGN\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1621\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CYTOCHROME C1, HEME PROTEIN, MITOCHONDRIAL PRECURSOR (CYTOCHROME C-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.150184\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.62682\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239596694\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CYC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1622\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
OLIGOPHRENIN-1 LIKE PROTEIN (GTPASE REGULATOR ASSOCIATED WITH FOCAL ADHESION KINASE). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0203871\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0850893\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239596518\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARHGAP26\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1623\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0163276\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0681463\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23959628\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARHGAP10\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1624\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CAMP-DEPENDENT PROTEIN KINASE TYPE II-BETA REGULATORY CHAIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.337407\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.40952\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239377235\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRKAR2B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1625\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN KINASE PKX1 (EC 2.7.1.-). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.143332\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.598798\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239366197\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRKX\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1626\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CAMP-DEPENDENT PROTEIN KINASE, GAMMA-CATALYTIC SUBUNIT (EC 2.7.1.37) (PKA C-GAMMA). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.190544\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.796037\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239365758\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRKACG\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1627\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CAMP-DEPENDENT PROTEIN KINASE, BETA-CATALYTIC SUBUNIT (EC 2.7.1.37) (PKA C-BETA). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.210706\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.880269\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.239365467\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRKACB\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1628\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT (EC 2.7.1.37) (PKA C-ALPHA). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
PRKACA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1629\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CAMP-DEPENDENT PROTEIN KINASE TYPE II-ALPHA REGULATORY CHAIN. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.392337\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.63914\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239355394\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PRKAR2A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1630\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.132038\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.551746\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239309392\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PHLPPL\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1631\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.167352\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.699345\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.2392982\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PHLPP\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1632\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRIPARTITE MOTIF PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.285075\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.19135\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239287363\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TRIM2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1633\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.938982\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.92552\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239199393\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
KIAA0368\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1634\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INOSITOL-1(OR 4)-MONOPHOSPHATASE 2 (EC 3.1.3.25) (IMPASE 2) (IMP 2) (INOSITOL MONOPHOSPHATASE 2) (MYO-INOSITOL MONOPHOSPHATASE A2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0919591\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.384447\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239198381\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
IMPA2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1635\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INOSITOL-1(OR 4)-MONOPHOSPHATASE (EC 3.1.3.25) (IMPASE) (IMP) (INOSITOL MONOPHOSPHATASE) (LITHIUM-SENSITIVE MYO-INOSITOL MONOPHOSPHATASE A1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.110487\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.461922\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239189733\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
IMPA1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1636\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MITOTIC CHECKPOINT PROTEIN BUB3. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.153821\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.64312\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239179313\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BUB3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1637\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ZINC FINGER PROTEIN 207. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0769103\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.32156\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239178691\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ZNF207\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1638\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASE REGULATORY SUBUNIT 6A (TAT-BINDING PROTEIN 1) (TBP-1) (PROTEASOME SUBUNIT P50). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.766353\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.20427\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239166175\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMC3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1639\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 7 (26S PROTEASOME REGULATORY SUBUNIT S12) (PROTEASOME SUBUNIT P40) (MOV34 PROTEIN HOMOLOG). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.790323\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.30538\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239102009\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMD7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1640\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ALPHA-FETOPROTEIN ENHANCER BINDING PROTEIN (AT MOTIF-BINDING FACTOR) (AT-BINDING TRANSCRIPTION FACTOR 1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0721691\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.301896\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239052853\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ZFHX3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1641\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UV EXCISION REPAIR PROTEIN RAD23 HOMOLOG A (HHR23A). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.101079\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.422881\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23902469\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAD23A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1642\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0488461\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.204356\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239024545\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1643\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.0624093\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.2611\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239024512\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DDI1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1644\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 4 (26S PROTEASOME REGULATORY SUBUNIT S5A) (RPN10) (MULTIUBIQUITIN CHAIN BINDING PROTEIN) (ANTISECRETORY FACTOR-1) (AF) (ASF). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.26742\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
5.30247\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239024455\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMD4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1645\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UV EXCISION REPAIR PROTEIN RAD23 HOMOLOG B (HHR23B) (XP-C REPAIR COMPLEMENTING COMPLEX 58 KDA PROTEIN) (P58). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.122909\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.514211\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239024447\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RAD23B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1646\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MYOSIN VI. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.050323\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.210535\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23902439\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
1647\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0275762\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.11537\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.23902401\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1648\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
INOSITOL POLYPHOSPHATE 5-PHOSPHATASE OCRL-1 (EC 3.1.3.36) (LOWE'S OCULOCEREBRORENAL SYNDROME PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0555683\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.23248\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.239024002\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
OCRL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1649\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.352885\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.47667\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238973501\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
COQ5\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1650\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CHAPERONE-ACTIVITY OF BC1 COMPLEX-LIKE, MITOCHONDRIAL PRECURSOR (CHAPERONE-ABC1-LIKE). \vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0340138\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.142333\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.238973393\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
CABC1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1651\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AARF DOMAIN CONTAINING KINASE 1. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
ADCK1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
1652\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AARF DOMAIN CONTAINING KINASE 2; PUTATIVE UBIQUINONE BIOSYNTHESIS PROTEIN AARF. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
ADCK2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1653\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
AARF DOMAIN CONTAINING KINASE 4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0274831\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.115005\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238973088\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ADCK4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1654\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 13 (26S PROTEASOME REGULATORY SUBUNIT S11) (26S PROTEASOME REGULATORY SUBUNIT P40.5). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.75685\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.16764\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238931823\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PSMD13\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1655\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
APURINIC/APYRIMIDINIC ENDONUCLEASE 2; APURINIC/APYRIMIDINIC ENDONUCLEASE-LIKE 2; APEX NUCLEASE-LIKE 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0730689\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.305877\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238883277\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
APEX2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1656\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COPPER-TRANSPORTING ATPASE 1 (EC 3.6.3.4) (COPPER PUMP 1) (MENKES DISEASE-ASSOCIATED PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0806616\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.337708\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238850131\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ATP7A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
1657\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CYCLIN M2; ANCIENT CONSERVED DOMAIN PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.317455\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.3291\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.238849597\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CNNM2\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/